Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Differential Impact of Lower Urinary Tract Symptoms on Generic and Disease-Specific Quality of Life in Men and Women

Araki I.a · Tsuchida T.a · Nomura T.a · Fukasawa M.a · Takihana Y.a · Koyama N.b · Takeda M.a

Author affiliations

aDepartment of Urology, Faculty of Medicine, University of Yamanashi, Chuo, and bClinical Pharmacology and Biostatistics Department, Sankyo Co. LTD., Tokyo, Japan

Related Articles for ""

Urol Int 2008;81:60–65

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 15, 2006
Accepted: April 27, 2007
Published online: July 16, 2008
Issue release date: July 2008

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: We investigated how generic and disease-specific measures differ in estimating the quality of life (QoL) impact of lower urinary tract symptoms (LUTS). Materials and Methods: A total of 172 men and 67 women ≧40 years old who attended the public lectures completed the questionnaire comprising the International Prostate Symptom Score, benign prostatic hyperplasia impact index and SF-36 Health Survey. The multiple regression analysis was performed to evaluate the QoL impact of LUTS. Results: Both storage and voiding symptoms showed significant correlations with disease-specific QoL. Among men, voiding symptom correlated more closely with disease-specific QoL than storage symptom did, and this finding was reversed among women. Storage but not voiding symptoms showed a significant correlation with generic QoL. Among men, storage symptom correlated more closely with mental health than physical health, and the reversed finding was obtained among women. Generic QoL, especially physical health, was significantly influenced by some comorbid diseases, but disease-specific QoL was not. Conclusions: The QoL impact of LUTS was differentially estimated by disease-specific and generic measures with sex differences.

© 2008 S. Karger AG, Basel


References

  1. Hunter DJW, McKee M, Black NA, Sanderson CFB: Health status and quality of life of British men with lower urinary tract symptoms: results from SF-36. Urology 1995;45:962–971.
  2. Peters TJ, Donovan JL, Kay HE, Abrams P, De La Rosette JJMCH, Porru D, Thüroff JW, the International Continence Society ‘Benign Prostatic Hyperplasia’ Study Group: The International Continence Society ‘Benign Prostatic Hyperplasia’ Study: the bothersomeness of urinary symptoms. J Urol 1997;157:885–889.
  3. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagier P-P, Guess HA, Rhodes T, Boyle P, Lieber MM: Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428–436.
  4. Schatzl G, Temml C, Waldmüller J, Thürridl T, Haidinger G, Madersbacher S: A comparative cross-sectional study of lower urinary tract symptoms in both sexes. Eur Urol 2001;40:213–219.
  5. Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E: The relationships among filling, voiding subscores from International Prostate Symptom Score and quality of life in Japanese elderly men and women. Eur Urol 2002;42:498–505.
  6. Welch G, Weinger K, Barry MJ: Quality of life of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002;59:245–250.
  7. Boyle P, Robertson C, Mazzeta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C, the UrEpik Study Group: The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int 2003;92:575–580.
  8. Masumori N, Homma D, Tsukamoto T: Web-based research of lower urinary tract symptoms that affect quality of life in elderly Japanese men: analysis using a structural equation model. BJU Int 2005;95:1013–1022.
  9. Barry MJ, Batista JE, Donovan J, Jonas U, Kurth KH, Lukacs B, Norman R, O’Leary M, Prezioso D, Richard F, Tsukamoto T: Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatment; in Chatelain C, Denis L, Foo KT, Khoury S, Mc Connell J (eds): Benign Prostatic Hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth, Plymbridge, 2000, pp 201–225.
  10. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, the Measurement Committee of the American Urological Association: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995;33:AS145–AS155.
    External Resources
  11. Barry MJ: Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001;58(suppl 6A):25–32.
    External Resources
  12. Ware JE, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903–912.
  13. Araki I, Zakoji H, Komuro M, Furuya Y, Fukasawa M, Takihana Y, Takeda M: Lower urinary tract symptoms in men and women without underlying disease causing micturition disorder: a cross-sectional study assessing the natural history of bladder function. J Urol 2003;170:1901–1904.
  14. Terai A, Matsui Y, Ichioka K, Ohara H, Terada N, Yoshimura K: Comparative analysis of lower urinary tract symptoms and bother in both sexes. Urology 2004;63:487–491.
  15. Welch G, Kawachi I, Barry MJ, Giovannucci E, Colditz GA, Willett WC: Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the Health Professionals Follow-up Study. Urology 1998;51:422–427.
  16. Alonso J, Ferrer M, Gandek B, Ware JE Jr, Aaronson NK, Mosconi P, Rasmussen NK, Bullinger M, Fukuhara S, Kaasa S, Leplège A, the IQOLA Project Group: Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 2004;13:283–298.
  17. Ware JE Jr, Gandek B, Koshinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M, Thunedborg K: The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from IQOLA Project. J Clin Epidemiol 1998;51:1167–1170.
  18. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 Health Profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33:AS264–AS279.
    External Resources
  19. Fukuhara S, Suzukama Y, Bito S, Kurokawa K: Manual of SF-36 Japanese Version 1.2. Tokyo, Public Health Research Foundation, 2001.
  20. Eckhardt MD, van Venrooij GEPM, van Melick HHE, Boon TA: Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol 2001;166:563–568.
  21. Mozes B, Maor Y, Shmueli A: The competing effects of disease states on quality of life of the elderly: the case of urinary symptoms in men. Qual Life Res 1999;8:93–99.
  22. Coyne KS, Zhou Z, Thompson C, Versi E: The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003;92:731–735.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 15, 2006
Accepted: April 27, 2007
Published online: July 16, 2008
Issue release date: July 2008

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.